Zacks: Brokerages Expect Infinity Pharmaceuticals, Inc. (INFI) to Announce -$0.20 EPS

Brokerages expect that Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) will announce ($0.20) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Infinity Pharmaceuticals’ earnings, with estimates ranging from ($0.21) to ($0.19). Infinity Pharmaceuticals reported earnings of ($0.34) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 41.2%. The firm is expected to announce its next earnings results on Thursday, August 2nd.

According to Zacks, analysts expect that Infinity Pharmaceuticals will report full-year earnings of ($0.74) per share for the current financial year, with EPS estimates ranging from ($0.77) to ($0.71). For the next fiscal year, analysts forecast that the business will report earnings of ($0.69) per share, with EPS estimates ranging from ($0.88) to ($0.59). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Infinity Pharmaceuticals.

Get Infinity Pharmaceuticals alerts:

Infinity Pharmaceuticals (NASDAQ:INFI) last announced its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.18).

Separately, Zacks Investment Research downgraded Infinity Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday.

In other news, major shareholder Value Fund L. P. Biotechnology purchased 1,510,000 shares of the company’s stock in a transaction dated Tuesday, April 10th. The shares were purchased at an average price of $1.97 per share, with a total value of $2,974,700.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 11.45% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. purchased a new position in shares of Infinity Pharmaceuticals during the 3rd quarter valued at $135,000. Alambic Investment Management L.P. purchased a new position in shares of Infinity Pharmaceuticals during the 4th quarter valued at $158,000. Wells Fargo & Company MN lifted its position in shares of Infinity Pharmaceuticals by 654.7% during the 4th quarter. Wells Fargo & Company MN now owns 105,136 shares of the biotechnology company’s stock valued at $213,000 after buying an additional 91,206 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Infinity Pharmaceuticals by 102.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 150,375 shares of the biotechnology company’s stock valued at $305,000 after buying an additional 75,980 shares during the last quarter. Finally, Clear Harbor Asset Management LLC purchased a new position in shares of Infinity Pharmaceuticals during the 4th quarter valued at $312,000. 47.35% of the stock is currently owned by hedge funds and other institutional investors.

Infinity Pharmaceuticals remained flat at $$1.99 during trading on Friday, Marketbeat reports. The company’s stock had a trading volume of 369,500 shares, compared to its average volume of 677,495. The company has a market cap of $116.63 million, a P/E ratio of -2.40 and a beta of 2.50. Infinity Pharmaceuticals has a 52-week low of $0.93 and a 52-week high of $3.75.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)